insights_auto
Why is ALMKT down 2.82%?
Dive Deeperchevron_right
ALMKT:EPA
Mauna Kea Technologies SA
€0.093
arrow_downward
-2.82%(-0.0027) 1D
Oct 26, 11:58:27 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
17.34M
Avg. vol.
457.74K
Volume
273.64K
P/E ratio
0.79
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
17.34M
Avg. vol.
457.74K
Volume
273.64K
P/E ratio
0.79
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
Reuters
·
55 minutes ago
Mapping the Market: Nasdaq losing its grip on rally
Seeking Alpha
·
1 hour ago
GPIX: One Of The Better S&P 500-Based Income ETFs (NASDAQ:GPIX)
Yahoo Finance
·
11 hours ago
Cramer Beat the S&P At His Hedge Fund But Advises Retail to Join The Index
Traders Union
·
40 minutes ago
Nasdaq rally shows technical strain near record high
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA